MA50201A - Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants - Google Patents

Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Info

Publication number: MA50201A
Authority: MA; Morocco
Prior art keywords: deferiprone; delayed; related methods; release tablets; tablets
Prior art date: 2017-10-25

Application number

MA050201A

Other languages

English (en)

Other versions

MA50201B1 (fr

Inventor

Michael Spino

Original Assignee

Chiesi Farm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-25

Filing date

2018-10-25

Publication date

2021-04-28

2018-10-25 Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa

2021-04-28 Publication of MA50201A publication Critical patent/MA50201A/fr

2025-07-31 Publication of MA50201B1 publication Critical patent/MA50201B1/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA50201A 2017-10-25 2018-10-25 Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants MA50201B1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201762577055P	2017-10-25	2017-10-25
US201762596043P	2017-12-07	2017-12-07
PCT/IB2018/058350 WO2019082128A1 (fr)	2017-10-25	2018-10-25	Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
EP18871663.3A EP3684344B1 (fr)	2017-10-25	2018-10-25	Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Publications (2)

Publication Number	Publication Date
MA50201A true MA50201A (fr)	2021-04-28
MA50201B1 MA50201B1 (fr)	2025-07-31

Family

ID=66170815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA50201A MA50201B1 (fr)	2017-10-25	2018-10-25	Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Country Status (30)

Country	Link
US (8)	US20200253945A1 (fr)
EP (2)	EP3684344B1 (fr)
JP (1)	JP7246384B2 (fr)
KR (1)	KR102624627B1 (fr)
CN (2)	CN111918646B (fr)
AU (1)	AU2018357350B2 (fr)
BR (1)	BR112020008128A2 (fr)
CA (2)	CA3077514C (fr)
DK (1)	DK3684344T3 (fr)
ES (1)	ES3036967T3 (fr)
FI (1)	FI3684344T3 (fr)
HR (1)	HRP20251151T1 (fr)
HU (1)	HUE073016T2 (fr)
IL (2)	IL273955B2 (fr)
LT (1)	LT3684344T (fr)
MA (1)	MA50201B1 (fr)
MD (1)	MD3684344T2 (fr)
MX (1)	MX2020004107A (fr)
MY (1)	MY204588A (fr)
NZ (2)	NZ787785A (fr)
PH (1)	PH12020550815A1 (fr)
PL (1)	PL3684344T3 (fr)
PT (1)	PT3684344T (fr)
RS (1)	RS67157B1 (fr)
SA (1)	SA520411808B1 (fr)
SG (1)	SG11202003153TA (fr)
SI (1)	SI3684344T1 (fr)
SM (1)	SMT202500358T1 (fr)
UA (1)	UA126977C2 (fr)
WO (1)	WO2019082128A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111918646B (zh)	2017-10-25	2022-02-22	奇斯药制品公司	延迟释放去铁酮片剂及其使用方法
EP4507679A1 (fr)	2022-04-11	2025-02-19	Chiesi Farmaceutici S.p.A.	Formulations pharmaceutiques à libération modifiée comprenant de la défériprone
US12016850B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
AU2023254403A1 (en)	2022-04-11	2024-11-21	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
KR20250073694A (ko)	2022-10-14	2025-05-27	키에시 파르마슈티시 엣스. 피. 에이.	데페리프론을 포함하는 변형 방출 약제학적 제제
WO2024240775A1 (fr)	2023-05-25	2024-11-28	Chiesi Farmaceutici S.P.A.	Formes galéniques pharmaceutiques pour libération pulsatile

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI98343C (fi) *	1995-03-21	1997-06-10	Orion Yhtymae Oy	Peroraalinen formulaatio
US5747532A (en)	1995-11-21	1998-05-05	Medinox, Inc.	Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
GB9625638D0 (en)	1996-12-10	1997-01-29	Cenes Ltd	Therapeutic antioxidants for alzheimer's diease
AP2002002546A0 (en)	1999-12-30	2002-06-30	Judith K Gwathmey	Iron chelator delivery system.
CA2313270C (fr)	2000-06-30	2011-09-13	Apotex Inc.	Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer
WO2004006856A2 (fr)	2002-07-12	2004-01-22	The Buck Institute For Research On Aging	Sequestration ou elimination du fer pour reduire la neurodegenerescence ou la progression de la maladie de parkinson
US8268352B2 (en)	2002-08-05	2012-09-18	Torrent Pharmaceuticals Limited	Modified release composition for highly soluble drugs
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
JP4757024B2 (ja)	2002-11-07	2011-08-24	テクニオンリサーチアンドディベラップメントファウンデイションリミテッド	神経保護鉄キレート剤及びそれを含む医薬組成物
JP2008509149A (ja) *	2004-08-06	2008-03-27	シババイオメディカル，エルエルシー	造影剤の注入を受けるヒトの処置方法
GB0502475D0 (en) *	2005-02-07	2005-03-16	Sb Pharmco Inc	Novel compositions
PL1991225T3 (pl)	2006-02-22	2014-04-30	Apotex Tech Inc	Zastosowanie deferypronu i sposobów w leczeniu i/lub zapobieganiu ataksji Friedreicha związanej z wewnątrzkomórkową nieprawidłową gospodarką żelazem
MX2009002235A (es)	2006-08-30	2009-03-13	Jagotec Ag	Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina.
WO2008027557A2 (fr) *	2006-08-31	2008-03-06	Spherics, Inc.	Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité
US20080138440A1 (en) *	2006-11-29	2008-06-12	Cormedix Inc.	Methods of diagnosing and alleviating gadolinium toxicity
CN101352438A (zh)	2007-07-25	2009-01-28	复旦大学	去铁酮及其制剂在制备防治蒽环类药物心脏毒性药物中的用途
AP2010005454A0 (en)	2008-04-25	2010-12-31	Apotex Technologies Inc	Liquid formulation for deferiprone with palatable taste.
US20110189260A1 (en)	2008-05-30	2011-08-04	University Of Cincinnati	Use of zinc chelators to inhibit biofilm formation
WO2010005851A1 (fr)	2008-07-08	2010-01-14	Xenon Pharmaceuticals Inc.	Polythérapie destinée au traitement de troubles du fer
WO2010014502A1 (fr) *	2008-07-31	2010-02-04	Aptapharma, Inc.	Comprimés cassables revêtus fonctionnellement
EP2206506A1 (fr)	2008-12-18	2010-07-14	Bracco Imaging S.p.A	Formulations probiotiques
AP2011005843A0 (en)	2009-01-26	2011-08-31	Joshua Lawrence Dunaief	Use of deferiprone for treatment and prevention ofiron-related eye disorders.
US8603814B2 (en)	2009-07-20	2013-12-10	Rutgers The State University Of New Jersey	Method of inhibiting nonsense-mediated mRNA decay
WO2011032000A2 (fr)	2009-09-10	2011-03-17	New York University	Procédé permettant d'empêcher des médicaments antimicrobiens et anticancéreux d'être inactivés par l'oxyde nitrique
US8563035B2 (en) *	2010-05-05	2013-10-22	Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi	Oral tablet compositions of dexlansoprazole
AU2012204213A1 (en)	2011-01-07	2013-06-13	Merrion Research Iii Limited	Pharmaceutical compositions of iron for oral administration
DE102011112898A1 (de)	2011-09-08	2013-03-14	Charité - Universitätsmedizin Berlin	Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
AU2012327224A1 (en)	2011-11-18	2013-06-06	Apotex Technologies Inc.	Methods of treatment with deferiprone
WO2013139931A1 (fr)	2012-03-21	2013-09-26	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Composition destinée à être utilisée dans le traitement de maladies neurodégénératives ayant des syndromes parkinsoniens
CN104955482A (zh) *	2012-11-12	2015-09-30	希普拉有限公司	包含地拉罗司和去铁酮的固定剂量的药物组合物
HK1215191A1 (zh)	2013-05-10	2016-08-19	Cipla Limited	低剂量医药组合物
ES2895044T3 (es) *	2013-06-06	2022-02-17	Albion Laboratories Inc	Suplemento de hierro
ITMI20132066A1 (it)	2013-12-11	2015-06-12	Farmatron Ltd	Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
KR102480882B1 (ko)	2016-08-05	2022-12-26	아브페로 파마슈티칼스, 인크.	금속-매개 상태를 치료하기 위한 투여 요법
US20180362228A1 (en) *	2017-02-16	2018-12-20	Jeffrey D. Jacobson	Container closure with integrated utensil
CN111918646B (zh)	2017-10-25	2022-02-22	奇斯药制品公司	延迟释放去铁酮片剂及其使用方法

2018
- 2018-10-25 CN CN201880069331.7A patent/CN111918646B/zh active Active
- 2018-10-25 MA MA50201A patent/MA50201B1/fr unknown
- 2018-10-25 NZ NZ787785A patent/NZ787785A/en unknown
- 2018-10-25 MD MDE20200792T patent/MD3684344T2/ro unknown
- 2018-10-25 EP EP18871663.3A patent/EP3684344B1/fr active Active
- 2018-10-25 DK DK18871663.3T patent/DK3684344T3/da active
- 2018-10-25 KR KR1020207014502A patent/KR102624627B1/ko active Active
- 2018-10-25 CA CA3077514A patent/CA3077514C/fr not_active Expired - Fee Related
- 2018-10-25 MX MX2020004107A patent/MX2020004107A/es unknown
- 2018-10-25 HR HRP20251151TT patent/HRP20251151T1/hr unknown
- 2018-10-25 CA CA3172668A patent/CA3172668A1/fr not_active Withdrawn
- 2018-10-25 BR BR112020008128-0A patent/BR112020008128A2/pt unknown
- 2018-10-25 MY MYPI2020002003A patent/MY204588A/en unknown
- 2018-10-25 CN CN202210164525.3A patent/CN114533689A/zh active Pending
- 2018-10-25 JP JP2020523267A patent/JP7246384B2/ja active Active
- 2018-10-25 PT PT188716633T patent/PT3684344T/pt unknown
- 2018-10-25 SM SM20250358T patent/SMT202500358T1/it unknown
- 2018-10-25 SI SI201831250T patent/SI3684344T1/sl unknown
- 2018-10-25 IL IL273955A patent/IL273955B2/en unknown
- 2018-10-25 ES ES18871663T patent/ES3036967T3/es active Active
- 2018-10-25 HU HUE18871663A patent/HUE073016T2/hu unknown
- 2018-10-25 EP EP25186255.3A patent/EP4635573A2/fr active Pending
- 2018-10-25 IL IL321388A patent/IL321388A/en unknown
- 2018-10-25 US US16/759,254 patent/US20200253945A1/en not_active Abandoned
- 2018-10-25 US US16/171,170 patent/US10940116B2/en active Active
- 2018-10-25 LT LTEPPCT/IB2018/058350T patent/LT3684344T/lt unknown
- 2018-10-25 RS RS20250792A patent/RS67157B1/sr unknown
- 2018-10-25 UA UAA202003078A patent/UA126977C2/uk unknown
- 2018-10-25 NZ NZ763555A patent/NZ763555A/en unknown
- 2018-10-25 WO PCT/IB2018/058350 patent/WO2019082128A1/fr not_active Ceased
- 2018-10-25 FI FIEP18871663.3T patent/FI3684344T3/fi active
- 2018-10-25 SG SG11202003153TA patent/SG11202003153TA/en unknown
- 2018-10-25 AU AU2018357350A patent/AU2018357350B2/en active Active
- 2018-10-25 US US16/171,173 patent/US10780055B2/en active Active
- 2018-10-25 PL PL18871663.3T patent/PL3684344T3/pl unknown
2019
- 2019-12-13 US US16/714,520 patent/US11458103B2/en active Active
2020
- 2020-04-03 US US16/839,928 patent/US11357731B2/en active Active
- 2020-04-20 PH PH12020550815A patent/PH12020550815A1/en unknown
- 2020-04-21 SA SA520411808A patent/SA520411808B1/ar unknown
- 2020-05-12 US US15/930,373 patent/US10940115B2/en active Active
2021
- 2021-05-21 US US17/327,135 patent/US11723874B2/en active Active
2022
- 2022-05-12 US US17/742,960 patent/US11607389B2/en active Active

Also Published As

Publication number	Publication date
SMT202500358T1 (it)	2025-11-10
US20190125682A1 (en)	2019-05-02
US20220265559A1 (en)	2022-08-25
ES3036967T3 (en)	2025-09-25
FI3684344T3 (fi)	2025-10-08
IL273955B2 (en)	2025-11-01
PL3684344T3 (pl)	2025-10-27
KR20200077542A (ko)	2020-06-30
CA3077514C (fr)	2022-10-11
IL273955B1 (en)	2025-07-01
SA520411808B1 (ar)	2023-02-16
CA3077514A1 (fr)	2019-05-02
PH12020550815A1 (en)	2021-07-05
US20200253945A1 (en)	2020-08-13
AU2018357350A1 (en)	2020-04-30
US10780055B2 (en)	2020-09-22
MA50201B1 (fr)	2025-07-31
WO2019082128A1 (fr)	2019-05-02
CN111918646B (zh)	2022-02-22
BR112020008128A2 (pt)	2020-11-03
CN111918646A (zh)	2020-11-10
US10940115B2 (en)	2021-03-09
JP7246384B2 (ja)	2023-03-27
EP3684344B1 (fr)	2025-07-02
UA126977C2 (uk)	2023-03-01
EP3684344A1 (fr)	2020-07-29
HUE073016T2 (hu)	2025-12-28
MY204588A (en)	2024-09-05
PT3684344T (pt)	2025-08-04
MX2020004107A (es)	2020-07-24
US20200188309A1 (en)	2020-06-18
RS67157B1 (sr)	2025-09-30
US11723874B2 (en)	2023-08-15
US10940116B2 (en)	2021-03-09
US20190117581A1 (en)	2019-04-25
CN114533689A (zh)	2022-05-27
IL321388A (en)	2025-08-01
KR102624627B1 (ko)	2024-01-16
LT3684344T (lt)	2025-09-10
AU2018357350B2 (en)	2023-09-21
DK3684344T3 (da)	2025-08-04
US20200268672A1 (en)	2020-08-27
EP4635573A2 (fr)	2025-10-22
US20200237674A1 (en)	2020-07-30
SI3684344T1 (sl)	2025-09-30
HRP20251151T1 (hr)	2025-12-05
JP2021500377A (ja)	2021-01-07
US11607389B2 (en)	2023-03-21
US11458103B2 (en)	2022-10-04
SG11202003153TA (en)	2020-05-28
US20210386677A1 (en)	2021-12-16
EP3684344A4 (fr)	2020-11-18
MD3684344T2 (ro)	2025-09-30
NZ787785A (en)	2025-11-28
CA3172668A1 (fr)	2019-05-02
US11357731B2 (en)	2022-06-14
NZ763555A (en)	2022-07-01
IL273955A (en)	2020-05-31

Publication	Publication Date	Title
EP3695037A4 (fr)	2021-07-07	Machine à tresser et ses procédés d'utilisation
MA50201A (fr)	2021-04-28	Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
EP3634430A4 (fr)	2021-04-14	Agents multibiotiques et procédés d'utilisation de ceux-ci
EP3526379A4 (fr)	2020-06-17	Machine à tresser et ses procédés d'utilisation
EP3303634A4 (fr)	2019-03-20	Variants de cas9 et procédés d'utilisation associés
EP3652325A4 (fr)	2021-09-15	Polynucléotides encapsulés et procédés d'utilisation
EP3684423A4 (fr)	2021-06-30	Virus adéno-associé à variant de capsides et leurs procédés d'utilisation
EP3436048A4 (fr)	2019-11-27	Néoantigènes et leurs procédés d'utilisation
EP3487379A4 (fr)	2020-04-01	Dispositifs médicaux et procédés d'utilisation
EP3364946A4 (fr)	2019-06-26	Systèmes à demeure gastriques pour libération prolongée d'agents thérapeutiques et leurs procédés d'utilisation
MA42043A (fr)	2018-03-14	Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA43018A (fr)	2021-06-02	Anticorps anti-pd1 et procédés d'utilisation
EP3394065A4 (fr)	2019-07-10	Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3377612A4 (fr)	2019-07-24	Expression fonctionnelle de monooxygénases et procédés d'utilisation
EP3510040A4 (fr)	2020-06-03	Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3635000A4 (fr)	2021-04-14	Manabodies et procédés d'utilisation
MA45280A (fr)	2019-01-09	Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
EP3303435A4 (fr)	2019-02-20	Hydrofluoroléfines et procédés d'utilisation associés
EP3515879A4 (fr)	2020-06-10	Équipement de durcissement avancé et procédés d'utilisation de celui-ci
EP3402493A4 (fr)	2019-08-21	Composition d'organoïde neural et procédés d'utilisation
EP3380181A4 (fr)	2019-07-17	Cathéter à gaine orientable et procédés d'utilisation associés
EP3271352A4 (fr)	2019-03-27	Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
EP3710430A4 (fr)	2021-06-23	Inhibiteurs d'acss2 et leurs procédés d'utilisation
EP3349851A4 (fr)	2019-04-24	Polypeptides photosensibles et leurs procédés d'utilisation
EP3307172A4 (fr)	2019-05-22	Cathéters d'imagerie intravasculaire et procédés d'utilisation correspondants